市场调查报告书
商品编码
1383399
到 2030 年基因编辑市场预测:按产品、技术、应用、最终用户和地区进行的全球分析Gene Editing Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球基因编辑市场规模为 74.5 亿美元,预计预测期内年复合成长率为 17.5%,到 2030 年将达到 230.5 亿美元。
一组被称为「基因编辑」的技术允许研究人员修改生物体的 DNA。这些技术使得改变、添加或去除基因组内特定位置的遗传物质成为可能。基因组编辑对于人类疾病预防和治疗来说是一个有吸引力的领域。更复杂的疾病,如癌症、心臟病、精神疾病和爱滋病毒感染疾病,也可以使用这项技术来治疗或预防。
根据美国国立卫生研究院 (NIH) 的数据,大约有 7,000 种罕见疾病影响着 2500 至 3000 万美国人。
基因组学越来越多地用于测试食品品质和安全。基因组编辑技术对于发现新药物以及识别和治疗人类遗传疾病至关重要。 NGS、DNA 分析和分析以及动植物基因工程都采用基因组编辑。在评估鱼类族群时,NGS 可用于 DNA 条码来识别鱼卵和幼虫,或全面表征鱼类群落。因此,在预测期内,随着基因组分析应用领域的扩大,对基因组编辑技术的需求可能会增加。
基因编辑疗法的研究和开发成本高且耗时。公司和组织可能很难筹集彻底的初步测试和临床试验所需的资金。基因编辑药物的开发很大程度上依赖临床试验,而临床试验的费用相当昂贵。这些试验通常涉及多个阶段和大量人员,需要证明基因编辑疗法的安全性和有效性。因此,高成本是市场拓展的主要障碍。
推动基因编辑市场的主要因素之一是遗传疾病盛行率的上升。这一趋势的本质特征是被诊断出患有罕见疾病和各种遗传性疾病的人数增加。 CRISPR-Cas9等基因编辑技术能够识别和纠正导致这些疾病的潜在遗传异常,因此患者终于可以看到希望。这些因素正在推动市场需求。
基因编辑技术的一个显着限制是CRISPR技术的脱靶效应。儘管 CRISPR-Cas9 可以以令人难以置信的精确度靶向特定基因,但它也可能导致预期目标以外的位置发生意外修改。由于这种脱靶活性,CRISPR技术的应用可能会带来风险和困难。这些因素都阻碍了市场的扩张。
这场大流行使基因编辑产业受益,因为社交距离规范和医院床位短缺迫使家庭患者照护系统充分适应。 COVID-19大流行彻底改变了我们的生活。它也进一步加速了科学界对创造力和协作的承诺。随着疫情在世界各地蔓延,科学家正忙于开发治疗方法、疫苗接种和诊断方法。科学家们正在转向高通量实验室自动化、人工智慧和机器学习来应对导致 COVID-19 的新型冠状病毒 SARS-CoV-2。 SARS-CoV-2 对于隔离感染患者并观察适当的医疗反应是必要的。因此,基因编辑市场受益于 COVID-19 的爆发。
试剂和消耗品部分估计占最大份额。试剂和消耗品包括各种物品,例如箔片密封件、玻片支架、板、晶片、管条、文库製备、精製和目标富集套件。由于基因组学在各行业的应用不断增长,预计消耗品市场将会成长。文库製备技术的进步也使得 NGS 在磊晶和转录组学中的应用成为可能。这些试剂盒用于定序应用,例如标靶定序和全基因组定序。
预计聚集的等距短回文重复片段将在预测期内实现良好的成长。作为传统基因修饰方法的替代方法,CRISPR 成簇的规则间隔截断回文重复序列已成为基因编辑的重要工具。 Cas9 酶是 CRISPR 与传统 DNA 编辑的不同之处。 CRISPR 透过去除受损或不必要的 DNA 序列来重新排列基因,使剩余的 DNA 呈现新的配置。
在估计期间,北美占据了最大的市场占有率。基因编辑最重要的区域市场是北美。美国是该地区的主要收益来源。在美国,创业投资、政府机构和私人公司正在基因编辑领域进行大量资金和投资。这笔资金筹措加速了基因编辑技术的研究、开发和商业化。治疗性介入的发展和基因编辑操作的扩展是由于资金筹措的提供而成为可能的。
预计亚太地区在预测期内将出现盈利成长。这是由于技术突破的增加、新兴地区生物技术产业的崛起以及癌症和其他遗传异常盛行率的上升而推动的。 CRISPR技术创新在日本仍在显着成长。同时,新兴的 CRISPR 研究预计将推动印度市场的成长。此外,印度研究人员也开发了广泛使用的 CRISPR-Cas9 基因编辑方法的不同变异。这种变异可以提高基因编辑的精确度,而不会导致意外的 DNA 变化。因此,这些变数预计将影响未来年度的亚太基因编辑市场。
介绍
促进因素
抑制因素
机会
威胁
产品分析
技术分析
应用分析
最终用户分析
新兴市场
新型冠状病毒感染疾病(COVID-19)的影响
According to Stratistics MRC, the Global Gene Editing Market is accounted for $7.45 billion in 2023 and is expected to reach $23.05 billion by 2030 growing at a CAGR of 17.5% during the forecast period. A group of technologies known as "gene editing" enables researchers to modify an organism's DNA. These technologies make it possible to change, add, or remove genetic material at particular locations within the genome. Genome editing is a fascinating field for both illness prevention and treatment in humans. More complicated conditions like cancer, heart disease, mental illness, and HIV infection may also be treated and prevented by using it.
According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.
Genomics is increasingly being used in food quality and safety testing. Technologies for editing genomes are essential for both finding new drugs and identifying and treating genetic diseases in humans. NGS, DNA analysis and profiling, and genetic engineering of plants and animals all employ genome editing. When evaluating fish populations, NGS can be utilized for DNA barcoding to identify fish eggs and larvae as well as to fully characterize fish communities. Therefore, during the projection period, there will likely be a rise in demand for genome editing technologies due to the expanding application areas of genomics.
Gene editing therapy research and development can be costly and time-consuming. It could be difficult for businesses and organizations to get the financing needed for in-depth pre- and clinical testing. The development of gene editing medicine heavily relies on clinical studies, which are quite expensive. These trials, which usually involve several phases and a large number of people, are required to show the safety and effectiveness of gene editing therapy. Therefore, high costs are a significant barrier to market expansion.
One major factor fueling the gene editing market is the increase in the prevalence of genetic illnesses. An increase in the number of people receiving diagnoses for uncommon diseases and different genetic disorders essentially characterizes this trend. Patients may finally have hope due to gene editing technologies like CRISPR-Cas9, which have the ability to identify and fix the underlying genetic abnormalities causing these illnesses. These factors propel market demand.
A significant constraint of gene editing technology is the off-target impacts of CRISPR technology. Although CRISPR-Cas9 can target certain genes with astonishing precision, it can also cause unintentional alterations at places other than the intended target. The application of CRISPR technology may present risks and difficulties as a result of this off-target activity. These factors hinder market expansion.
The industry for gene editing benefited from the pandemic because social distancing norms and a shortage of hospital beds forced home-based patient care systems to adapt to the fullest. The COVID-19 pandemic has changed our lives. It has also intensified the already swift inclinations toward creation and cooperation among the scientific community. With the pandemic spreading across the globe, scientists are working feverishly to develop treatments, vaccinations, and diagnoses. To tackle SARS-CoV-2, the new coronavirus that causes COVID-19, scientists are looking into high-throughput experimental automation, artificial intelligence, and machine learning. The SARS-CoV-2 is necessary for isolating infected patients and observing appropriate medical responses. Thus, the market for gene editing benefited from the COVID-19 epidemic.
The reagents & consumables segment is estimated to hold the largest share. Reagents and consumables encompass a wide range of items, including foil seals, slide holders, plates, chips, tube strips, library preparation, purification, and target enrichment kits. The market for consumables is predicted to rise as a result of genomics' expanding applicability in a variety of industries. Utilizing NGS in epigenetic and transcriptomics has also been made possible by developments in library preparation technology. Applications for sequencing, including targeted and whole-genome sequencing, employ these kits.
The clustered regularly interspaced short palindromic repeats segment is anticipated to have lucrative growth during the forecast period. As an alternative to conventional genetic alteration methods, CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats have become an essential tool for gene editing. The Cas9 enzymes set CRISPR apart from previous types of DNA editing. By removing damaged or undesirable DNA sequences, CRISPR reorganizes genes so that the remaining DNA can take on new configurations.
North America commanded the largest market share during the extrapolated period. The most significant regional market for gene editing is North America. The US has become this region's main source of revenue. In the US, venture capitalists, governmental organizations, and private companies have made large financial and investment contributions in the gene editing field. Research and development, as well as the commercialization of gene editing technologies, have been accelerated by this financing. The development of therapeutic interventions and the expansion of gene editing businesses have been made possible by the availability of funding.
Asia Pacific is expected to witness profitable growth over the projection period. This is due to increasing technological breakthroughs, a thriving biotechnology industry in emerging regions, and the rising prevalence of cancer and other genetic abnormalities. Innovation in CRISPR technology is still growing significantly in Japan. On the other hand, new CRISPR research is anticipated to propel market growth in India. Additionally, researchers in the nation developed a distinct variation of the widely used CRISPR-Cas9 gene-editing method. The variant may increase the accuracy of gene editing without causing unintended DNA changes. Therefore, in the upcoming years, it is anticipated that these variables will have an effect on the Asia-Pacific gene editing market.
Some of the key players in the Gene Editing Market include: Sangamo Therapeutics, Inc., Beam Therapeutics, Integrated DNA Technologies, Inc., Thermo Fisher Scientific, Horizon Discovery Ltd., Precision Biosciences, CRISPR Therapeutics, GeneScript, Agilent Technologies, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Lonza, Perkinelmer, Editas, edicine, Tecan Life Sciences, Amsbio and Creative Biogene.
In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.
In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.
In February 2023, Gen Script (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company's advanced gene-synthesis capability and enables Gen Script to provide the service levels required for novel vaccine and therapeutic development in life sciences.
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19